Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems

From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The European journal of health economics 2015-03, Vol.16 (2), p.113-118
Hauptverfasser: von der Schulenburg, J.-Matthias Graf, Frank, Martin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 118
container_issue 2
container_start_page 113
container_title The European journal of health economics
container_volume 16
creator von der Schulenburg, J.-Matthias Graf
Frank, Martin
description From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.
doi_str_mv 10.1007/s10198-014-0639-8
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1658706412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>24773846</jstor_id><sourcerecordid>24773846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</originalsourceid><addsrcrecordid>eNp9kMtr3DAQh0VJaB7tH9BDiyCXXJyOJOuVWwh5FAKB0B6LkOVxdxevnWq8h_3vo63zKD0UBJKYb34zfIx9EnAmAOxXEiC8q0DUFRjlK_eOHQojXGUNiL2Xt_bugB0RrQCktFK9ZwdSK62l14fs50PMyJfEu4y_NzhMPA7t26cU0khTvz3neQe2S8JISDyWw9Mi9j0Ov5B3Y-YLjP204GnH0ZYmXNMHtt_FnvDj833Mflxffb-8re7ub75dXtxVSSs3VU1jU7QIKKEFYbtkmhpiEzuvEiTrMXrlQZoojFKqdrZpRKfB2NrbtmuFOmanc-5jHsviNIX1khL2fRxw3FAQRjsLphayoCf_oKtxk4ey3R8KtAddF0rMVMojUcYuPOblOuZtEBB27sPsPhT3Yec-uNLz5Tl506yxfe14kV0AOQNUSsVa_mv0f1I_z00rmsb8Flpbq1xt1BMFzZe8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1658059054</pqid></control><display><type>article</type><title>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>JSTOR Archive Collection A-Z Listing</source><creator>von der Schulenburg, J.-Matthias Graf ; Frank, Martin</creator><creatorcontrib>von der Schulenburg, J.-Matthias Graf ; Frank, Martin</creatorcontrib><description>From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.</description><identifier>ISSN: 1618-7598</identifier><identifier>EISSN: 1618-7601</identifier><identifier>DOI: 10.1007/s10198-014-0639-8</identifier><identifier>PMID: 25355295</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer</publisher><subject>Collaboration ; Cost analysis ; Delivery of Health Care - economics ; Delivery of Health Care - organization &amp; administration ; Disease ; Drug Industry - economics ; Drugs ; Economic Policy ; EDITORIAL ; Enzymes ; Europe ; Genomes ; Health care ; Health care access ; Health care expenditures ; Health Care Management ; Health care policy ; Health Economics ; Health Planning - organization &amp; administration ; Humans ; Life expectancy ; Medicine ; Medicine &amp; Public Health ; Mutation ; Patient Preference ; Patients ; Pharmaceutical industry ; Pharmacoeconomics and Health Outcomes ; Physicians ; Public Finance ; Public Health ; Rare diseases ; Rare Diseases - economics ; Rare Diseases - epidemiology ; Reimbursement ; Statistical data</subject><ispartof>The European journal of health economics, 2015-03, Vol.16 (2), p.113-118</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><rights>Springer-Verlag Berlin Heidelberg 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</citedby><cites>FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/24773846$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/24773846$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,781,785,804,27928,27929,41492,42561,51323,58021,58254</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25355295$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>von der Schulenburg, J.-Matthias Graf</creatorcontrib><creatorcontrib>Frank, Martin</creatorcontrib><title>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</title><title>The European journal of health economics</title><addtitle>Eur J Health Econ</addtitle><addtitle>Eur J Health Econ</addtitle><description>From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.</description><subject>Collaboration</subject><subject>Cost analysis</subject><subject>Delivery of Health Care - economics</subject><subject>Delivery of Health Care - organization &amp; administration</subject><subject>Disease</subject><subject>Drug Industry - economics</subject><subject>Drugs</subject><subject>Economic Policy</subject><subject>EDITORIAL</subject><subject>Enzymes</subject><subject>Europe</subject><subject>Genomes</subject><subject>Health care</subject><subject>Health care access</subject><subject>Health care expenditures</subject><subject>Health Care Management</subject><subject>Health care policy</subject><subject>Health Economics</subject><subject>Health Planning - organization &amp; administration</subject><subject>Humans</subject><subject>Life expectancy</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mutation</subject><subject>Patient Preference</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pharmacoeconomics and Health Outcomes</subject><subject>Physicians</subject><subject>Public Finance</subject><subject>Public Health</subject><subject>Rare diseases</subject><subject>Rare Diseases - economics</subject><subject>Rare Diseases - epidemiology</subject><subject>Reimbursement</subject><subject>Statistical data</subject><issn>1618-7598</issn><issn>1618-7601</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kMtr3DAQh0VJaB7tH9BDiyCXXJyOJOuVWwh5FAKB0B6LkOVxdxevnWq8h_3vo63zKD0UBJKYb34zfIx9EnAmAOxXEiC8q0DUFRjlK_eOHQojXGUNiL2Xt_bugB0RrQCktFK9ZwdSK62l14fs50PMyJfEu4y_NzhMPA7t26cU0khTvz3neQe2S8JISDyWw9Mi9j0Ov5B3Y-YLjP204GnH0ZYmXNMHtt_FnvDj833Mflxffb-8re7ub75dXtxVSSs3VU1jU7QIKKEFYbtkmhpiEzuvEiTrMXrlQZoojFKqdrZpRKfB2NrbtmuFOmanc-5jHsviNIX1khL2fRxw3FAQRjsLphayoCf_oKtxk4ey3R8KtAddF0rMVMojUcYuPOblOuZtEBB27sPsPhT3Yec-uNLz5Tl506yxfe14kV0AOQNUSsVa_mv0f1I_z00rmsb8Flpbq1xt1BMFzZe8</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>von der Schulenburg, J.-Matthias Graf</creator><creator>Frank, Martin</creator><general>Springer</general><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</title><author>von der Schulenburg, J.-Matthias Graf ; Frank, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c538t-bb7ca7e0e20d017fc6b40abaf93c0c79ea939026a16333487bb1f5067497dfd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Collaboration</topic><topic>Cost analysis</topic><topic>Delivery of Health Care - economics</topic><topic>Delivery of Health Care - organization &amp; administration</topic><topic>Disease</topic><topic>Drug Industry - economics</topic><topic>Drugs</topic><topic>Economic Policy</topic><topic>EDITORIAL</topic><topic>Enzymes</topic><topic>Europe</topic><topic>Genomes</topic><topic>Health care</topic><topic>Health care access</topic><topic>Health care expenditures</topic><topic>Health Care Management</topic><topic>Health care policy</topic><topic>Health Economics</topic><topic>Health Planning - organization &amp; administration</topic><topic>Humans</topic><topic>Life expectancy</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mutation</topic><topic>Patient Preference</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pharmacoeconomics and Health Outcomes</topic><topic>Physicians</topic><topic>Public Finance</topic><topic>Public Health</topic><topic>Rare diseases</topic><topic>Rare Diseases - economics</topic><topic>Rare Diseases - epidemiology</topic><topic>Reimbursement</topic><topic>Statistical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von der Schulenburg, J.-Matthias Graf</creatorcontrib><creatorcontrib>Frank, Martin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The European journal of health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von der Schulenburg, J.-Matthias Graf</au><au>Frank, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems</atitle><jtitle>The European journal of health economics</jtitle><stitle>Eur J Health Econ</stitle><addtitle>Eur J Health Econ</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>16</volume><issue>2</issue><spage>113</spage><epage>118</epage><pages>113-118</pages><issn>1618-7598</issn><eissn>1618-7601</eissn><abstract>From an economic point of view, the health care system should achieve the following goals: efficient production of health care, just distribution of resources and stable financing. The current intensive discussion on rare diseases demonstrates the difficulty in achieving all three goals at the same time. Rare diseases collectively are frequent. That is why they are an extraordinary financial and organizational challenge for payers. The treatment of patients with rare diseases is either very costly and/or extremely difficult. For many of those diseases, no effective therapy exists.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer</pub><pmid>25355295</pmid><doi>10.1007/s10198-014-0639-8</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1618-7598
ispartof The European journal of health economics, 2015-03, Vol.16 (2), p.113-118
issn 1618-7598
1618-7601
language eng
recordid cdi_proquest_miscellaneous_1658706412
source MEDLINE; SpringerNature Journals; JSTOR Archive Collection A-Z Listing
subjects Collaboration
Cost analysis
Delivery of Health Care - economics
Delivery of Health Care - organization & administration
Disease
Drug Industry - economics
Drugs
Economic Policy
EDITORIAL
Enzymes
Europe
Genomes
Health care
Health care access
Health care expenditures
Health Care Management
Health care policy
Health Economics
Health Planning - organization & administration
Humans
Life expectancy
Medicine
Medicine & Public Health
Mutation
Patient Preference
Patients
Pharmaceutical industry
Pharmacoeconomics and Health Outcomes
Physicians
Public Finance
Public Health
Rare diseases
Rare Diseases - economics
Rare Diseases - epidemiology
Reimbursement
Statistical data
title Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T17%3A40%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rare%20is%20frequent%20and%20frequent%20is%20costly:%20rare%20diseases%20as%20a%20challenge%20for%20health%20care%20systems&rft.jtitle=The%20European%20journal%20of%20health%20economics&rft.au=von%20der%20Schulenburg,%20J.-Matthias%20Graf&rft.date=2015-03-01&rft.volume=16&rft.issue=2&rft.spage=113&rft.epage=118&rft.pages=113-118&rft.issn=1618-7598&rft.eissn=1618-7601&rft_id=info:doi/10.1007/s10198-014-0639-8&rft_dat=%3Cjstor_proqu%3E24773846%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1658059054&rft_id=info:pmid/25355295&rft_jstor_id=24773846&rfr_iscdi=true